76 related articles for article (PubMed ID: 20850175)
1. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.
Barak F; Milgrom R; Laitman Y; Gemer O; Rabinovich A; Piura B; Anteby E; Baruch GB; Korach J; Friedman E
Gynecol Oncol; 2010 Dec; 119(3):511-5. PubMed ID: 20850175
[TBL] [Abstract][Full Text] [Related]
2. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
3. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
4. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
6. Risk of endometrial carcinoma associated with BRCA mutation.
Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
[TBL] [Abstract][Full Text] [Related]
7. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
[TBL] [Abstract][Full Text] [Related]
8. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
9. A636P is associated with early-onset colon cancer in Ashkenazi Jews.
Guillem JG; Rapaport BS; Kirchhoff T; Kolachana P; Nafa K; Glogowski E; Finch R; Huang H; Foulkes WD; Markowitz A; Ellis NA; Offit K
J Am Coll Surg; 2003 Feb; 196(2):222-5. PubMed ID: 12595050
[TBL] [Abstract][Full Text] [Related]
10. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
11. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel.
Figer A; Irmin L; Geva R; Flex D; Sulkes J; Sulkes A; Friedman E
Br J Cancer; 2001 Feb; 84(4):478-81. PubMed ID: 11207041
[TBL] [Abstract][Full Text] [Related]
12. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
13. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
15. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
16. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
17. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
Kaufman DJ; Beaty TH; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1045-52. PubMed ID: 14578141
[TBL] [Abstract][Full Text] [Related]
18. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]